Journal of Contemporary Brachytherapy
eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
3/2025
vol. 17
 
Share:
Send email
Share:
abstract:
Original paper

Brachytherapy for eyelid cancers: Re-defining outcomes and esthetics in rare histologies

Sarbani Ghosh Laskar
1
,
Anuj Kumar
1
,
Prashasti Sharma
1
,
Ashwini Budrukkar
1
,
Monali Swain
1
,
Shwetabh Sinha
1
,
Samarpita Mohanty
1
,
Muhammed Anaz
2
,
Shrikant Kale
2

  1. Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
  2. Department of Medical Physics, Tata Memorial Centre, Mumbai, India
J Contemp Brachytherapy 2025; 17, 3: 174–182
DOI: https://doi.org/10.5114/jcb.2025.152540
Online publish date: 2025/06/30
View full text Get citation
 
Purpose:
To evaluate local control, cosmetic outcomes, toxicities, and survival outcomes of interstitial high-dose-rate (HDR) brachytherapy treatment in non-basal cell carcinoma malignancies of the eyelid.

Material and methods:
This retrospective study analyzed patients with histopathologically confirmed eyelid malignancies treated with adjuvant HDR interstitial brachytherapy (192Ir) between August 2007 and August 2024. Outcomes assessed included loco-regional control (LRC), disease-free survival (DFS), overall survival (OS), and toxicities graded by the Radiation Therapy Oncology Group (RTOG). Kaplan-Meier analysis estimated survival rates, while cosmetic outcomes were evaluated using cosmetic assessment of intraocular brachytherapy (CAIB) scale.

Results:
Eighteen patients with sebaceous (72.2%) and squamous (22.2%) histologies received 21-49 Gy in 7-14 frac-tions (3-3.5 Gy/fraction). With a median follow-up of 21.93 (IQR, 10.6-152.83) months, no loco-regional recurrences were observed among 13 patients with documented follow-up (LRC, 100%). Two patients died (one from systemic progression without local failure and the other from COVID-19), and three were lost to follow-up. The 5-year OS and DFS rates were 83.3%. Cosmetic outcomes were rated excellent in 55.55% and very good in 44.44% of patients. No grade 3 and above acute toxicities occurred, and eyelid/eye function was preserved in 88.88% (16/18), ensuring organ preservation without late toxicity.

Conclusions:
Adjuvant HDR brachytherapy is a safe and effective treatment for eyelid malignancies, achieving excellent local control, superior cosmetic outcomes, and acceptable toxicity. This modality optimizes tumor control, while preserving function and esthetics in this anatomically sensitive region.

keywords:

cosmesis, brachytherapy, outcomes, adjuvant, eyelid

  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.